Prelude Therapeutics Inc
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
PRLD$3.60+1.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets (Unaudited)
BALANCE SHEETS
| (in thousands, except share data) | March 31,2026 | December 31,2025 |
|---|---|---|
| Assets · (unaudited) | ||
| Current assets: | ||
| Cash and cash equivalents | $21,756 | $35,256 |
| Marketable securities | 59,798 | 67,958 |
| Prepaid expenses and other current assets | 3,039 | 2,478 |
| Total current assets | 84,593 | 105,692 |
| Restricted cash | 3,235 | 3,235 |
| Property and equipment, net | 4,722 | 5,113 |
| Right-of-use asset | 26,778 | 27,165 |
| Prepaid expenses and other non-current assets | 314 | 110 |
| Total assets | $119,642 | $141,315 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $2,069 | $3,983 |
| Accrued expenses and other current liabilities | 5,938 | 12,533 |
| Deferred revenue | 30,952 | 33,734 |
| Operating lease liability | 2,761 | 2,744 |
| Total current liabilities | 41,720 | 52,994 |
| Deferred revenue, net of current portion | — | 1,798 |
| Other liabilities | 2,779 | 2,841 |
| Operating lease liability | 14,960 | 15,045 |
| Total liabilities | 59,459 | 72,678 |
| Commitments (Note 8) | ||
| Stockholders’ equity: | ||
| Voting common stock, $0.0001 par value: 487,149,741 shares authorized; 48,290,087 and 48,225,493 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 5 | 5 |
| Non-voting common stock, $0.0001 par value: 112,850,259 shares authorized; 14,728,135 shares issued and outstanding at both March 31, 2026 and December 31, 2025 | 1 | 1 |
| Additional paid-in capital | 753,664 | 751,684 |
| Accumulated other comprehensive (loss) income | (41) | 8 |
| Accumulated deficit | (693,446) | (683,061) |
| Total stockholders’ equity | 60,183 | 68,637 |
| Total liabilities and stockholders’ equity | $119,642 | $141,315 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.